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The search for novel, pharmacologically significant compounds is a perpetual quest 
on which biologists, chemists, and bioinformaticians incessantly embark. The sources of 
these compounds are often of natural origin, making bioprospecting an enticing area of 
research. One such source of these natural compounds are lichens, which can produce a 
plethora of bioactive compounds. Historically, lichens have been held as medicine in 
traditional healing, while in modern times, research has begun to lend validity to these 
claims. The aim of this thesis was to extract, separate, identify, and evaluate the anti-cancer 
and antibiotic activity of numerous bioactive compounds and extracts from North American 
lichens. Antibacterial efficacy was analyzed via resazurin reduction assay, while anticancer 
ability was evaluated using the MTT assay and propidium iodide flow cytometry. The lichens 
studied include Xanthoparmelia mexicana, Lobothallia alphoplaca, and Umbilicaria 
muhlenbergii. Results from the crude acetone maceration extracts of the lichen showed 
promise of antibacterial activity against gram-positive bacteria (Xanthoparmelia mexicana, 
MIC of 41.9 μg mL-1 and 20.9 μg mL-1 against E. faecalis and S. aureus, respectively) while 
other crude extracts showed promising anticancer activity (Lobothallia alphoplaca, IC50 of 
87.0 μg mL-1 against MCF-7 cells, MTT assay). Furthermore, Umbilicaria muhlenbergii 
showed bioactive prowess against both gram-positive bacteria and cancerous cells, with an 
MIC of 22.5 μg mL-1 against S. aureus and an IC50 of 13.3 μg mL-1 against MCF-7 cells. Due to 
it’s marked bioactivity, Umbilicaria muhlenbergii crude extract was further separated with 
silica gel 60 column chromatography, where multiple fractions were found to be bioactive 




separated with Sephadex LH-20, yielding multiple fractions which exhibited bioactivity 
against select bacteria, in addition to anti-cancer abilities and cell-cycle arrest abilities. 
Further studies will need to be undertaken to fully identify compounds from and evaluate 
the bioactivity of the lichen extracts investigated.  
Lay Summary 
 The fight against common infections and cancers is an endless endeavour 
undertaken by researchers every day. To combat these ailments, novel treatments and 
pharmaceutical compounds must be discovered and tested. An incredibly important 
contributor to these new treatments are natural products, which are pharmaceutically 
relevant compounds that come from a natural source. The diverse range of organisms these 
compounds are obtained from is expansive, and often the organism’s natural components 
are analyzed to determine if they’ll be useful as drugs. In this particular thesis, an often 
overlooked area of natural products research, lichens, were investigated for anticancer and 
antibiotic properties. The extracted complex mixtures of these chemically uncharacterized 
North American lichens were also separated into individual components to identify the 
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1.1 Thesis Objectives 
 The three main objectives of this thesis were to determine if the three lichen species 
evaluated contain bioactive molecules, to determine which bioactive qualities each of these 
lichens possess, and lastly to identify which compounds are responsible for this bioactivity.  
 To achieve these objectives, three chemically undescribed North American lichens 
were investigated for bioactivity against several bacteria and MCF-7 adenocarcinoma cells. 
The lichens were evaluated for bioactivity against Staphylococcus aureus, Pseudomonas 
aeruginosa, and Enterococcus faecalis bacteria, and a MCF-7 adenocarcinoma breast cancer 
cell line.   
 The three lichens were collected from three different locations (Figure 1-1). Two of 
the lichens, Xanthoparmelia mexicana (Figure 1-2) and Lobothallia alphoplaca (Figure 1-3), 
were collected by Mr. Kerry Knudsen of University of California Riverside Lichen Herbarium. 
Xanthoparmelia mexicana was collected from Catalina Island, California, USA, while 
Lobothallia alphoplaca was collected from Joshua Tree National Park, California, USA. The 
Umbilicaria muhlenbergii lichen (Figure 1-4) was collected from Thunder Bay, Ontario, 
Canada by Dr. Lada Malek of Lakehead University.   
 As the project progressed, a more refined and pointed investigation into the 
separation of Umbilicaria muhlenbergii extract into fractions, then evaluating and identifying 





Figure 1-1: Locations of lichens collected. Xanthoparmelia mexicana (triangle), Lobothallia 
alphoplaca (square), Umbilicaria muhlenbergii (star). 





Figure 1-2: Xanthoparmelia mexicana lichen. 
 

















2 Literature Review  
2.1 Natural Products 
 Since the beginning of mankind, botanical and natural sources have been utilized to 
treat ailments, whether through purposeful discovery or serendipitous ingestion2. Some of 
the earliest records of natural product use date to Mesopotamia in 2600 B.C., where the oils 
of myrrh and cypress were used to treat coughs and colds 3. A few hundred years later, the 
ancient Egyptians created a pharmaceutical record known as the Ebers Papyrus. The Ebers 
Papyrus contains over 700 plant-based drugs and their doses for a plethora of ailments, in 
addition to numerous other medical observations and procedures 4. These ancient texts 
were complimented by the likes of the Chinese Materia medica and Indian Materia medica, 
as the knowledge of these treatments began to travel the world.  5, 6. The Greco-Roman 
empire, centuries later, built upon the findings of more ancient civilizations, with many 
Greek and Roman physicians and scientists contributing more knowledge, such as the 
Historia plantarum by Theophrastus, De Materia Medica by Pedanius Dioscorides, and 
volumes of records by Claudius Galenus 7. There are countless other examples of 
pharmaceutical records as one searches nearer to the current millennia, making this list 
even more non-exhaustive. As world-wide literacy increased steadily throughout the 
centuries, more and more treatments can be found mentioned in the folklore of all cultures. 
One can trawl the history of any human culture to have lived, and will find some use of 
natural products for a medicinal and/or pharmaceutical purpose. This ubiquitous endeavour 





 These traditional oral and written pharmaceutical histories have been a foundation 
for modern pharmaceuticals, with many being further developed and verified by clinical, 
pharmacological, biological, and chemical studies 1, 8. These include compounds which 
exhibit antibiotic, antifungal, antiviral, antiretroviral, anticancer, antioxidant, antiparastic, 
immunostimulating, pesticide, insecticide, and larvicidal bioactivities9-17. While those of 
ancient times sought relief from their ailments via observational analysis, brute force 
testing, or pure serendipity, our modern fields of medicine, biology, chemistry, and 
pharmacology have turned to more advanced methods of useful natural product 
identification. This modern approach to the age-old venture has proved quite fruitful, as 
many common pharmaceuticals in use today come from a naturally derived source 18.  
 Examples of these naturally-derived modern pharmaceuticals abound, with 
applications in everything from pain mitigation to cancer treatment18. Some well-known 
naturally derived pharmaceuticals include aspirin, digitoxin, morphine, quinine, pilocarpine, 
paclitaxel, artemisinin, reserpine, vinblastine, and atropine 8, 11, 18, 19. Many of these 
compounds are produced by the organism for functions apart from those required to sustain 





Figure 2-1: Structures of commonly used, naturally derived pharmaceuticals21. 
  
 These naturally derived compounds make up a significant portion of novel 
pharmaceuticals, as evidenced by recent and regular investigations 7, 19-23.  The most recent 
of these reviews focused on specific anticancer drugs between 1981 and 2014, and drugs for 
all diseases between 1981 and 2014 21. Between the years 1981 and 2014, 1,562 new 
chemical entities were approved for pharmaceutical use, with a majority being from natural 
sources 21. As shown in Figure 2-2, only 27% of all novel pharmaceuticals within the last 34 
years have been purely synthetic in origin21. While completely chemically unaltered natural 
and botanical products make up only 20% of all novel approved drugs, natural products still 
play a significant role 21. They provide researchers with molecules to mimic, model, and 





Figure 2-2: All new approved drugs, 1981-2014, n=156221. 
B: biological macromolecule, N: Unaltered natural product, NB: Botanical drug of defined 
mixture, ND: natural product derivative, S: Synthetic drug, S*: Synthetic drug with a 
natural product pharmacophore, V: vaccine, /NM: mimic of a natural product.  
 
 This reliance on natural products becomes even more pronounced when only anti-
cancer compounds are investigated. Between the 1940’s and 2014, 175 small molecules 
were approved for anticancer use, with 131 (75%) of those compounds being of non-
synthetic origin, and 85 (49%) of them being natural products or directly derived from 









Figure 2-4: All anticancer drugs from 1940 to 2014, n=24621. 
 
 The development of antibiotics is one research area which particularly blossomed 
due to natural products discovery. Following the 1928 discovery and subsequent synthetic 
production of penicillin in the 1940’s, companies began to realize that collections of 
Figure 2-3: Two common naturally-derived anti-





organisms could be the key to finding new antibiotics 1. These well-funded and well-
supported ventures quickly churned out drugs which are now considered pillars of a modern 
healthcare system. These include antibiotics such as streptomycin, chloramphenicol, 




 These naturally derived antibiotics have been in successful clinical use for decades, 
though the significance of some of them is beginning to wane 26. New strains of antibiotic 
resistant bacteria, such as vancomycin-resistant Enterococcus, methicillin-resistant 
Staphylococcus aureus, and multiple-drug resistant Mycobacterium tuberculosis, are inciting 





Figure 2-5: Naturally Derived Antibiotics1. 





 Common sources of pharmaceutical compounds have been trees, flowers, herbs, 
roots, berries, and fungi. Of particular interest to this investigation are lichens, as they are a 
promising source of novel secondary metabolites which haven’t yet been fully tapped 27.  
2.2 What are lichens? 
 As renowned lichenologist Trevor Goward once humorously stated, “lichens are 
fungi that have discovered agriculture”28. He is not too far off, as lichens are a composite 
organism consisting of a fungus that can harness the primary metabolic production of a 
photosynthetic partner29. Lichens are ubiquitously found throughout the globe, with the 
number of extant species estimates ranging from 17,000 to 20,000 29. They are known as 
“pioneer organisms”, as they can grow and flourish in incredibly harsh and inhospitable 
environments such as desert rocks, Antarctic wasteland, arctic tundra, tree bark, urban 
concrete, soils and countless other locations 30.  
2.2.1 Lichen Structure 
 Lichens are not one single organism, but an obligate mutualistic association between 
two partners: a photobiont and a mycobiont. The photobiont is an alga or cyanobacterium, 
while the mycobiont is a species of fungus29.  Once the two organisms are living 
harmoniously, the lichen will have its own morphology and physiology that will differ from 





Figure 2-6: Four main parts of a lichen. 
 
 The part of the lichen which attaches to the substrate is known as the lower cortex 
(Figure 2-6) 32. The lower cortex will often become so strongly attached to the substrate that 
any attempt at removal of the lichen will result in the removal of substrate along with the 
lichen 32. This attachment often occurs through the use of rhizines, which penetrate into the 
substrate33. Other types of lichen may use attachment methods such as plate-like thalli 29. 
Distal to the cortex, the mycobiont forms the medulla, where primary metabolites from the 
photobiont are stored by the mycobiont 29. The photobiont layer can be found within this 
area of the medulla (Fig 2-6), where the mycobiont can protect the photobiont from 
overexposure to sun, heat, pollution, and excess water, while simultaneously giving the 
photobiont ideal amounts of light and water to grow 29. In exchange for this ideal growth 
condition, the mycobiont uses the photobiont’s photosynthetically produced metabolites to 




cortex, is the part of the lichen which is visible to a passer-by29. It can vary quite drastically 
in shape, size, colour, and configuration, and therefore is often used as a means of 
classifying types of lichens 34.  
 The overall lichen structure is provided by a mycobiont component known as the 
thallus (or lichen body) 29, 35, 36. The differences in thallus structure can be classified into 
crustose, foliose, and fruticose types 29. These different thallus structures arise due to 
different photobionts and mycobionts interacting in different environments, resulting in 
variances of morphology. The thallus often has a thorough intermingling of the photobiont 
and mycobiont, giving them the appearance of one individual which is markedly different 
than its individual parts. The thallus is also markedly important to the search for natural 
products, as the thallus is where secondary metabolites, produced by the mycobiont, are 
always found29.  
 
 





 The thallus of the lichen is composed of small structures, strands of fungal cells 
known as hyphae (Figure 2-7), which extend both apically toward the outer cortex, and 
inwards into the photobiont29, 36. The hyphae extract nutrients from the photobiont on the 
inside, while also being a location of secondary metabolite production and deposition on the 
upper cortex 29, 35, 36. These secondary metabolites are often deposited onto the ends of the 
hyphae, where they can be found as either crystals or amorphous deposits (indicated by red 
dots in Figure 2-7). 
2.3 Metabolites in Lichens 
 The metabolites found in these lichens are a part of the overall symbiotic 
metabolism, which is composed of primary metabolites and secondary metabolites, with 
each serving very different purposes. The primary metabolites (Figure 2-8) are those which 
are necessary for the growth of the lichen, and include organic compounds such as proteins, 
lipids, and carbohydrates 37. These are produced by both the photobiont and the mycobiont 
29, 37. Secondary metabolites (Figure 2-8) are compounds which are metabolically non-
essential to the growth of the organism, but serve a function more suited to the 
evolutionary goals of long term survival and reduction of competition 34. These secondary 





Figure 2-8: Lichen Metabolic Pathway Leading to Lichen Secondary Metabolites39. 
  
 Lichen secondary metabolites are formed through either the acetyl polymalonyl 
pathway, the shikimic acid pathway, or the mevalonic acid pathway (Figure 2-8). Though the 
mechanistic intricacies of these pathways are beyond the context of this review, it is 
important to note the vast array of compounds which can be synthesized by lichens through 
these secondary metabolite pathways.  
2.3.1 Secondary Metabolite Variation 
 The plethora of combinations between primary and secondary metabolism within 
lichens result in a staggering number of compounds being produced. Interestingly, a 




in any other fungi, algae, or higher plants40-42. There is a vast amount of interspecies and 
intraspecies variation due to these complex pathways. The intraspecies variation is quite 
significant, as the aforementioned pathways result in the lichen incorporating compounds 
from the substrate into the secondary metabolic profile. The variances in the substrate can 
lead to two different lichens of the same species growing on different substrates to produce 
an entirely different cassette of different compounds in different concentrations 43-45. 
Currently, it is reported that there are approximately 1,050 known lichen secondary 
metabolites 40, 46. Commonly found compounds include phenolic compounds (e.g. orcinol 
and β-orcinol, anthraquinones (parietin), dibenzofurans (usnic acid), depsides (gyrophoric 
acid), depsidones (norstictic acid), depsones (picrolichenic acid), γ-lactones 
(protolichesterinic acid), and pulvinic acid derivatives (vulpinic acid) 34.  
 
Figure 2-9: Common groups of lichen secondary metabolites34.  
 
 A majority of these compounds are produced by the mycobiont, though a small 




mycobiont47. It is these complex arrangements of chemicals that contribute to the ultimate 
bioactivity of lichens.  
2.4 Lichen Constituent Bioactivities 
2.4.1 Historical and ethnobotanical significance of lichens 
 Lichens have been utilized for a variety of uses by humankind since prehistory, 
including dyes, perfumes, pH indicators, emergency food sources, and traditional medical 
remedies 48. 
 A significant barrier to lichen metabolites being incorporated into pharmaceutical 
applications is the inherent toxicity of many secondary metabolites. This has been 
exemplified by the toxicity of usnic acid, which was included in a weight-loss drug called 
Lipokinetix®. It was intended to cause an increase in metabolic rate, thereby increasing 
caloric usage and inducing weight loss 49. Clinical trials in which the drug was taken for 3 
months resulted in all test subjects developing acute severe hepatotoxicity, with one death 
being attributed to the drug 50, 51. After discontinuing ingestion of the drug, patients made 
full recoveries 49. Though the mechanism of hepatotoxicity was never fully resolved, usnic 
acid has been strongly linked to be the culprit. This lichen metabolite toxicity then brought 
into question the validity and safety of all lichenic substances used as drugs.  
 These toxic qualities of many of these lichen metabolites are not entirely prohibiting, 
as Umbilicaria muhlenbergii has been known to be used as an emergency food source and 
traditional medicine 52. The lichen is first boiled, presumably to extract any readily soluble 




of lichen substances will need to be undertaken as they run the gamut of in vitro and in vivo 
evaluation.  
2.4.2 Antioxidant 
Free radicals and reactive oxygen species can cause oxidative stress within the 
human body, resulting in harmful effects 53. It is often postulated that oxidative stress 
contributes to aging and an increased chance of disease and infection 53. One particular 
culprit is the presence of free radicals, which are known to cause a multitude of disorders in 
humans 34. Free radicals are molecular fragments which contain one or more unpaired 
electrons 53. They are incredibly reactive with metabolites involved in biochemical pathways, 
and attract electrons from other cellular components. This can lead to cellular damage, such 
as cancerous unchecked cell proliferation, and cell death. These free radicals and reactive 
oxygen species are normally neutralized within the body by naturally produced anti-oxidant 
compounds, though recent research has proposed that supplementary antioxidants could be 
beneficial 54. This has led to a body of research into supplemental antioxidants that can 
mitigate these effects. Natural products are being looked towards as a means of discovering 
novel antioxidant compounds, as many organisms, lichens included, produce many 
antioxidant compounds. In lichens, a significant number of the metabolites produced exhibit 
antioxidant and photoprotective abilities, making them an attractive target for investigation.  
Previous investigations into lichen antioxidants have yielded positive results 34. For 
example, species such as Peltigera rufescens had methanolic extracts exhibiting strong 
antioxidant potential. Other species have also followed suit, such as Acarospora socialis, 




Lobaria pulmonaria 55-59. In many of these instances, a correlation between phenolic content 
and antioxidant abilities has been noted55-57, 60.  
One compound, lecanoric acid, is often found in Umbilicaria species. It has 
prominent antioxidant potential, indicating that the Umbilicaria muhlenbergii lichen used in 
this investigation could be analyzed for antioxidant activity as well. Another lichen 
investigated, Xanthoparmelia mexicana, is noted to contain usnic acid, salazinic acid, 
consalazinic acid, and norstictic acid, all of which have exhibited in vitro antioxidant abilities 
to some degree54, 58, 59, 61, 62.  
In vivo research into lichen metabolite antioxidant effects has also been undertaken, 
though the field has not yet resulted in an abundance of findings.   
The literature on lichen antioxidants stretches both wide and deep, but some 
variance in lichen species and compounds is present.  These variances in the literature could 
be due to the antioxidant activity not being the result of single metabolites, but due to 
synergistic effects of multiple metabolites. This is also exemplified by crude extract 
evaluations showing more favourable antioxidant results than those of separated extracts 
and identified, purified compounds.  
2.4.3 Anticancer 
The realm of anticancer research is an expansive one, with many different target 
approaches to stopping the disease. Lichen metabolites are one small part of this large 
research endeavour, as their metabolites have begun to show some promise as potential 




compound which presents differential effects against cancerous cells, inhibiting their 
growth, while not affecting the growth of normal, non-cancerous cells. The target of these 
compounds is also a mechanism where apoptosis is induced, rather than necrosis of the cell. 
Selective apoptotic potential would lead to the compounds having an effect on cancerous 
cells, but not affecting regular cell growth.  
 This research into lichens has ramped up within the last 15 years, leading to a 
plethora of literature reports available on the anticancer effects of crude extracts 27, 34, 46, 63-
66. A review on specific lichen species to have been evaluated is not the focus of this thesis, 
so an exhaustive investigation will not be completed, though a multitude of publications are 
available which cover countless species. Further background research on the anticancer 
effects of the individual lichens investigated can be found below, in section 2.5, Lichen 
Species Investigated.  
Of more interest are the specific compounds from various lichens which have been 
assessed for anticancer activity. Particularly, the methods used for evaluation and the types 
of compounds which have bioactivity are of interest. This includes compounds such as usnic 
acid, protolichesterinic acid, atranorin, and physodic acid67, 68.  
Further investigation into lichen metabolites has not been extended greatly into the 
realm of in vivo work, though some experiments have been performed. One particular 
investigation found that lichen extracts did not cause toxic effects in mice, and did exhibit 






 Antibacterial activity is often cited as one of the most thoroughly investigated lichen 
bioactivities, owing to the large number of compounds, which appear to have antibacterial 
qualities. These compounds have been found to be effective against both gram-positive (G+) 
and gram-negative (G-) bacteria. The current spread of bacterial resistance, combined with 
the decreased funding towards novel antibiotic discovery, has led to a void in effective 
antibiotics coming in to play in modern healthcare.  
 The most prominent and thoroughly researched antibacterial is usnic acid 38, 70-72. 
The compound’s efficacy against G+ bacteria has been thoroughly investigated, and it has 
been incorporated as a natural product topical antibiotic agent in some countries 73.  
2.5 Lichen Species Investigated 
2.5.1 Xanthoparmelia mexicana 
 Xanthoparmelia mexicana is a foliose lichen which is commonly found throughout 
the western United States of America, Canada, and Mexico. It has been previously evaluated 






Figure 2-10: Structure of usnic acid74.  
 
Figure 2-11: Structure of salazinic acid75. 
 Usnic acid has been shown to possess anticancer abilities and antibacterial abilities74. 
Another abundant Xanthoparmelia mexicana metabolite, a depside called salazinic acid, has 
also shown antibacterial activity against both gram-positive and gram-negative bacteria34, 75.  
2.5.2 Lobothallia alphoplaca 
Lobothallia alphoplaca, a placodioid, areolate lichen species found throughout the 
USA and Canada, has three main metabolic constituents: salazinic acid, norstictic acid and 
constictic acid. Norstictic acid has previously been identified as possessing antimicrobial 
activity when extracted from Ramalina farinacea, Toninia candida, and Usnea barbata 




salazinic acid 75. The activities of these compounds, and the hopes for similar compounds 
within Lobothallia alphoplaca encouraged investigation into it’s bioactivities.  
2.5.3 Umbilicaria muhlenbergii 
 Umbilicaria muhlenbergii, a foliose lichen common throughout central and Eastern 
North America, is the third lichen subject of investigation. It is abundant throughout North 
America, and has been noted as a source of food throughout history, by both Europeans and 
Aboriginals in North America. It has been noted that the Cree of Manitoba prepared it by 
mixing flakes of lichen into fish broth, and eating the soup was considered a good meal for 
one that had a sick stomach 52. In Chipewyan of Saskatchewan culture, the flakes were 
burned slightly in a frying pan, mashed, then boiled down to make a syrup which was used 
to expel tapeworms from the body 79. The Thcho of the Northwest Territories used the 
lichen to produce a soup, which was then eaten as a tonic and as a treatment for breathing 
problems 80.  
 Other species within the genus Umbilicaria were also used for traditional purposes. 
The Dena’ina of Alaska and the Inuit of Northern Quebec boiled Umbilicaria lichen and used 
it as a drink to treat tuberculosis and prolonged bleeding, while the Ekuanitshit of Quebec 
made a tea with Umbilicaria sp. and used it to treat urinary proplems 80  It is eaten around 
the world as well, with some cultures treating it as a delicacy.   
 Though quite common, easy to collect, and noted for medicinal and food uses, 
Umbilicaria muhlenbergii lacks a comprehensive bioactivity assessment. It has been studied 




pertains to its ability to bind heavy metal compounds, in addition to studies on lichen 
primary metabolism 81-84. This predictable heavy metal incorporation behaviour has resulted 
in Umbilicaria muhlenbergii being utilized as a bioindicator organism of sorts, especially in 
regions where mining is prevalent 83, 85-88. Common metals investigated include mercury, 
nickel, cesium, copper, silver, and lead 83, 85, 86, 89, 90. It has also been used as a target 
organism in lichen species distribution studies, specifically those where the distribution of 
multiple lichen species in one area is of interest 91. These investigations were undertaken in 
the late 1970’s to late 1990’s, with little research being put into Umbilicaria muhlenbergii 
since that time.    
 The precedent set by its ethnobotanical uses, in addition to the lack of assessment 
into its bioactivities, make Umbilicaria muhlenbergii an enticing and promising prospect for 
study. Its anticancer and antimicrobial properties will be investigated, filling in a gap in the 
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 Previous investigation into North American lichens used for this publication had 
already begun by Erik Yeash, a graduate student under the supervision of Dr. Lew P. 
Christopher at the North Dakota School of Mines and Technology. Upon starting as the 
director of the Biorefining Research Institute in Thunder Bay, ON, Dr. Christopher 
resumed investigation of the bioactivities of North American lichens. For this 
publication, I was responsible for the acetone extraction of the lichens, MTT testing of 
the lichen crude extracts against MCF-7 breast cancer cells, and the MIC experiments 
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BACKGROUND: Lichens provide a large array of compounds with the potential for 
pharmaceutical development. In the present study, extracts from three previously 
undescribed North American lichen species were examined for antioxidant, antibacterial and 
anticancer activities.  
RESULTS: The results from this study demonstrated the following: 1) Acarospora socialis 
ethanol extract exhibited significant DPPH antioxidant scavenging activities of up to 88.6%; 
the antioxidant activities were concentration-dependent; 2) the acetone and ethyl acetate 
extracts of Xanthoparmelia mexicana inhibited Gram-positive bacteria with a zone of 
inhibition of up to 21 mm; the X. mexicana acetone extract yielded a minimum inhibitory 
concentration (MIC) of 20.9 ug mL-1 against Staphylococcus aureus, and 41.9 ug mL-1 against 
Enterococcus faecalis;  3) the acetone extract of Lobothallia alphoplaca inhibited growth of 
cultured breast cancer MCF-7 cells at a relatively low effective concentration (EC50) of 87 µg 
mL-1 ; the MCF-7 cell cycle appears arrested in the G2 phase whereas the DNA synthesis cell 
cycle (S) may be inhibited. 
 
CONCLUSION: New lichen species that possess strong biological activities have been 
characterized. Potential exists to develop new, potent and non-toxic antioxidant, 
antimicrobial and anticancer agents from naturally-occurring lichen metabolites that can 




3.5 Keywords: Lichens, North America, biological activities, Acarospora socialis, 
Xanthoparmelia mexicana, Lobothallia alphoplaca 
 
3.6 Introduction 
 Lichens and their diverse metabolic products provide a large array of compounds 
with the potential for pharmaceutical development.1 General characteristics of lichens and 
their historical ethnobotanical uses have been described previously.2 However, the search 
for novel antibiotic compounds and for anti-cancer compounds is particularly relevant in 
view of the spread of antibiotic resistant bacteria and the growing need for better and 
improved cancer drugs, respectively.  
 The antioxidant, antibacterial and anti-proliferative activities of lichens have been 
the focus of several reports. Generally, antioxidant activity may be relevant as a mechanism 
for reversing cellular damage induced by metabolic dysfunction or by external factors. 
Radical scavenging capacity by several lichen extracts was reported recently3, 4, as well as in 
older work using extracts from cultured lichen material.5 Reports by Turkez and co-workers6 
suggest protective role of lichen extracts against specific types of oxidative cell damage. 
 Search for lichen-derived antibiotic compounds started in the post-WWII era7 and 
continues until the present. Shrestha and St. Clair8 tabulated some of the more recent work 
and additional reports have appeared since.9-11  Unfortunately, of the hundreds of natural 
products investigated, only a few have reached clinical trials and none of these originated 




compounds. Commercial natural health products tend to be used topically, and internally 
consumed lichen extracts have proven toxic.13 
 Nevertheless, the toxicity of lichen extractives may yet turn out to be beneficial in 
relation to their potential use as anticancer drugs. Usnic acid, a common lichenic acid, is 
reported to have some effect against lung carcinoma in mice.14 Much of the work on 
cultured neoplastic cells performed between 1979 and 2012 has been summarized.8, 11 More 
recent investigations report anti-proliferative activity against a variety of cultured cell lines.8, 
10, 11, 15 To our knowledge, only two investigations included non-neoplastic cells as controls 
and showed a degree of selectivity (SI) of the lichen compounds against the transformed cell 
as compared to normal cells.16, 17 Studies on living model animals are rarely performed or 
reported, but of note is the report of inhibition of tumor angiogenesis by olivetoric acid.18 
 The objective of this study was to investigate the in vitro biological effects of lichens, 
with the expectation that further work will be possible to characterize the chemical nature 
of the active constituents and elucidate in some detail their mechanisms of action. Three 
lichen species occurring in Western United States, that have not been studied to date, were 
selected for investigation: Acarospora socialis, Xanthoparmelia mexicana and Lobothallia 
alphoplaca. The biological activity of these lichens was assessed by determining their 








 Two of the lichens, Acarospora socialis and Lobothallia alphoplaca, were obtained 
from Joshua Tree National Park in California whereas Xanthoparmelia mexicana was 
collected on Catalina Island, 22 miles south-west of Los Angeles, California. The images of 
the lichen species are depicted in Fig. 1. These species were collected and identified by 
lichenologist Kerry Knudsen, and voucher specimens deposited in the herbarium of 
University of California at Riverside, under accession numbers 15106.1, 15119.1, and 15436, 

















Figure 3-1: Lichens investigated: (A) Acarospora socialis (Tim Wheeler); (B) Lobothallia 









Chemicals and instruments 
 Extraction solvents, bacterial media, dimethyl sulfoxide (DMSO), and 2,2-diphenyl-1-
picrylhydrazyl (DPPH), and CellTiter-Blue® were purchased from Thermo Fisher Scientific, 
Waltham, MA, USA. Materials for cell viability staining including 3-(4,5-Dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium Bromide (MTT) and propidium iodide were obtained from Sigma-
Aldrich (St. Louis, MO, USA). The instruments utilized in this study included a Biotek 
PowerWaveXS microplate spectrophotometer (Biotek Instruments Inc., Winooski VT, USA), a 
BD ACCURI C6 flow cytometer (BD Biosciences, San Jose, CA, USA), and a BMG FLUOstar 
Optima Microplate Reader (BMG Labtech, Offenburg, Germany). 
 
Preparation of lichen extracts 
 Lichens were pulverized in mortar and pestle, the lichen powder was stirred with 100 
mg mL-1 solvent (99.5% ethanol, acetone or ethyl acetate) at 120 rpm and 37oC for 24 h in 
an Innova© R42 incubator shaker (New Brunswick, Connecticut, USA), and thereafter filtered 
through Whatman #1 filter paper. The extraction yield was calculated by subtracting the 
mass of the filtered solids from the original mass of ground lichen.  
 
Antioxidant activity  
 The procedures of Sharma and Bhat (2009) and Rankovic et al. (2011) were followed 




DPPH was prepared (in the same solvent as extract), 1 mL of the DPPH solution was mixed 
with 25 uL of solvent or extract and absorbency at 517 nm (A517) read in Shimadzu UV-2450 
spectrophotometer (Shimadzu Scientific, Maryland, USA) at 30 and 60 min. Results from 
three independent and parallel experiments were expressed as % absorbance compared to 
solvent only.  The DPPH radical concentration was calculated using the following equation: 
Antioxidant (DPPH-scavenging) activity (%) = [(A0 − A1)/A0] × 100 
where A0 is the absorbance of the negative control and A1 is the absorbance of the reaction 
mixture or standard. 
 
Anticancer activity 
Cell culture  
 Human breast cancer MCF-7 cells (ATCC HTB-22) were purchased from the American 
Type Cell Culture Collection (ATCC, Manassas, VA, USA) and maintained in supplemented 
Dulbecco's Modified Eagle Medium (DMEM). The DMEM was supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin. The cell line was incubated at 37oC with a 
humidified 5% CO2 atmosphere.  
Anticancer activity assay 
 MCF-7 cells were seeded in a 96-well tissue culture microplate at a density of 10,000 
cells per well, then incubated at 37oC under 5% CO2 for 24 h. Next, the lichen extract was 




reduce the amount of acetone used in the treatment. Upon the MCF-7 cells reaching 
confluency, the medium was removed from the wells and 200 µL of lichen extract diluted in 
non-supplemented DMEM was added in triplicate. The concentration of lichen metabolites 
in the treatments ranged from 5.39 µg mL-1 to 517.5 µg mL-1. Note that the lichen 
metabolite concentration must be expressed as a value of µg mL-1, as the active compounds 
have not yet been isolated and identified. For clarity, the concentration of the positive 
control, cis-diammineplatinum(II) dichloride (cisplatin) is given in both molar concentration 
and mass per volume concentration. Appropriate negatives and controls were also added. 
The positive control, cis-diammineplatium(II) dichloride (cisplatin), was prepared as a 198 ug 
mL-1 (0.66 mM) stock solution in sterile 0.9% NaCl solution. It was serially diluted from 0.6 
µg mL-1 (2 µM) to 24 µg mL-1 (80 µM) for treatment conditions. The negative control was an 
untreated control group of MCF-7 cells which were grown in non-supplemented DMEM. A 
12 mM solution of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) in 
phosphate buffered saline was prepared, filter sterilized, and stored in the dark at 4oC. The 
plate was incubated at 37oC and 5% CO2 atmosphere for 44 h, followed by the addition of 20 
µL of MTT solution to each well. Next, the plates were incubated at 37oC and 5% CO2 for 4 h. 
The MTT solution was then removed from each well and replaced with 50 µL of dimethyl 
sulfoxide (DMSO). The plates were covered in foil and mixed on a Belly Dancer for 10 min. 
The absorbance was then measured at 490 nm and 650 nm with a BioTek Powerwave XS 
spectrophotometer. To determine cell survival, the absorbance of the samples, controls, and 
negatives were measured and compared to baseline and negative control. All experiments 




Cell culture treatment and analysis 
 Cell cycle analysis was performed in triplicate by treating MCF-7 cells with 5 µL of 
extract per 200 µL media, incubating for 48 h, trypsinizing and collecting them, then fixing 
the cells with 70% ethanol. The fixed cells were then stained with propidium iodide (50 µg 
mL-1) for 30 min at room temperature. The cell cycle analysis was performed on a BD 
ACCURI C6 flow cytometer and was used to determine the frequency of cells which had their 
cell cycles in the G1, S and G2 phases.  
 
Antibacterial activity 
Microorganisms and media 
 Bacteria used as test organisms in this study included both Gram-positive 
(Streptococcus pyogenes, Staphylococcus aureus, Enterococcus faecalis) and Gram-negative 
bacteria (Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis). All bacteria were 
acquired from ATCC and stored at -80oC as a solution comprised of 50% glycerol and 50% 
cell suspension in Luria-Bertani (LB) broth.  
 When taken out of cryostorage, one loop of bacteria was streak plated on Mueller 
Hinton II  (MHII) agar and incubated at 37oC until individual colonies were sighted. Next, one 
colony was taken from the plate and used to inoculate 10 mL of MHII broth. The broth 
culture was incubated at 37oC until it reached a turbidity level which was equal to that of a 




Zone of inhibition 
 Initial tests as reported in Table 1 were carried out by agar disk diffusion tests, also 
commonly referred to as the Kirby-Bauer susceptibility procedure.21 The plates used were LB 
agar plates inoculated with bacterial isolates via cotton swab, which covered the entire agar 
surface with bacteria. The disks were sterile 6 mm sizes punches of Whatman® No. 1 filter 
paper, which was then loaded with lichen sample. Dry disks were prepared by pipetting 5 µL 
of 100 mg mL-1 extract (500 µg of lichen metabolites dissolved in 5 µL solvent) onto each 
disk, then the disks were dried until all the solvent evaporated, then they were placed on LB 
agar plates. The wet disks were prepared by placing sterile disks on the agar plates, then 5 
µL of 100 mg mL-1 extract (500 µg of lichen metabolites dissolved in 5 µL solvent) was 
pipetted onto the disk.  The plates were then immediately incubated at 37oC for 24 h. After 
incubation, the zone of inhibition was determined by measuring the diameter of the growth-
inhibited area with a ruler. Appropriate solvent control disks were evaluated as well. All 
experiments were performed in triplicate. The sensitivity of microorganisms to the acetone 
extracts of the investigated lichen species was tested by determining the 
minimal inhibitory concentration (MIC). 
Minimum Inhibitory Concentration (MIC) 
 The MIC was determined in triplicate as follows: an 18-h broth culture (37oC and 150 
rpm) was diluted to 10 x 106 CFU mL-1 and 100 µL added to microplate, together with lichen 
extract dilutions (from .86 µg/mL  to 860 µg mL-1) and appropriate solvent and negative 




spectrophotometer, followed by measuring the same plates incubated at 37oC for 24 h. At 
24 h, 40 µL of CellTiter-Blue® was added to each well of the microplate. The plates were 
incubated for 4 h at 37oC, then fluorescence was measured at 544 nm excitation/590 nm 
emission. To ensure accuracy of the spectrophotometer absorbance and fluorescence 
readings, 10 µL of each treatment condition were streaked onto LB agar plates, then 
incubated at 37oC for 24 h. After 24 h, the growth on each plate was noted.   
 
Statistical analyses 
 Statistical analyses were performed with the EXCEL, GraphPad Prism 6, and FlowJo 
software packages. To determine the statistical significance of antioxidant activity, Student’s 
t test was used. All values were expressed as mean ± standard deviation (SD) of three 
parallel measurements. To determine statistical significance of cell death, a two-sample t-
test assuming unequal variance was used.  
 
3.8 Results and Discussion 
Antioxidant activity 
 The antioxidant properties of both A. socialis ethanolic and methanolic extracts were 
more effective than any other extracts examined in this study (Fig. 2). Furthermore, the A. 
socialis ethanolic and methanolic extracts showed higher DPPH free radical scavenging 




There was a statistically significant difference between these extracts and the trolox control 
(P < 0.05). The X. mexicana acetone extract exhibited half the DPPH free radical scavenging 
activity of 1 mM trolox treatment, while the L. alphoplaca extracts did not show any 
significant antioxidant effects (Fig. 3-2). The antioxidant activities were concentration-
dependent and generally increased with the increase in the extract concentrations applied, 
although the increase did not follow any particular pattern and was dependent on the type 
of solvent and lichen used (data not shown).   
 
 
Figure 3-2: 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging ability of lichen 
extracts. Et, ethanol; Ac, acetone; EA- ethyl acetate; Met- methanol; Trolox, positive 
control. 
 Many compounds with marked antioxidant capabilities have been isolated from 
lichen species. The activities of these compounds have proven to be comparable to those of 




(depside), lobaric acid (depsidone) and lecanoric acid (depside)22. These compounds exhibit 
superoxide radical scavenging abilities very similar to that of a common antioxidant food 
additive, propyl gallate.22  Another study found that 8’-methylmenegazziaic acid and 
antranorin, both lichen-derived compounds, have antioxidant activities which are 
comparable in activity to a Trolox® standard.23 A lichen-derived bisnaphthoquinone, 
cuculloquinone, was found by another investigation to have 80% DPPH inactivation, which 
was twofold more effective than the butylated hydroxytoluene (BHT) standard it was 
compared to.24 As evident from Fig. 1, the Acarospora ethanolic extracts exhibited high 
antioxidant potential.  The other two lichen extracts tested, Lobothallia alphoplaca and 
Xanthoparmelia mexicana, did not exhibit statistically significant antioxidant abilities (data 
not shown). The results from our study and those of others25 have shown that naturally-
occurring lichen metabolites produce in vitro antioxidant effects similar to or exceeding 
those of common synthetic antioxidant compounds. The impetus of natural antioxidant 
research is to find novel and effective antioxidant compounds which do not exhibit 
carcinogenic effects, as some of the synthetic antioxidants do25.  
Antibacterial activity 
 The antibacterial activity of the lichen extracts against Gram-negative and Gram-
positive bacteria was evaluated using the disk diffusion method. None of the lichen extracts 
were active against Gram-negative bacteria (data not shown). In addition, the acetone and 
ethyl acetate extracts of X. mexicana were the only two extracts which showed antibiotic 
activity on Gram-positive bacteria (Table 1). All Lobothallia alphoplaca and Acarospora 




the solvent control disks did not show any significant zones of inhibition (data not shown). 
Hence, there was a statistically significant difference between the extracts and the solvent 
control (P < 0.05). Further investigation into the X. mexicana acetone extract using the 
microdilution assay yielded a MIC of 20.9 ug mL-1 against S. aureus, and 41.9 ug mL-1 against 
E. faecalis (data not shown). MIC tests performed with acetone controls showed no 
statistically significant effect on bacterial viability (P < 0.05). The fact that the X. mexicana 
extract lacked any activity against Gram-negative bacteria points towards a possible 
antibiotic mechanism involving the peptidoglycan cell wall of Gram-positive bacteria.   
 Table 1: Zone of Inhibition (mm) by X. mexicana extracts 
Solvent Methoda S. aureus (G+) S. pyogenes (G+) E. faecalis (G+) 
Acetone Dry 11 ± 0.5 18 ± 1.0 11 ± 0.5 
Acetone Wet 15 ± 1.0 20 ± 1.5 13 ± 1.0 
Ethyl acetate Dry 12 ± 0.5 19 ± 2.0 11 ± 1.0 
Ethyl acetate Wet 15 ± 1.0 21 ± 1.5 14 ± 1.5 
aWet, disk placed on agar before extract treatment; Dry, disk soaked in lichen extract, 
dried, then placed on agar. 
 
 The search for novel antibiotic compounds is critical26, given the spread of antibiotic 
resistance, particularly among bacteria acquired in hospitals.27 Screening for natural 
compounds in unusual sources such as lichens may provide new leads. Xanthoparmelia 
mexicana showed promise for further investigation of specific components of the crude 
extract. Examination of related species (Xanthoparmelia conspersa and Xanthoparmelia 
stenophylla) was not found to inhibit growth of pathogenic fungi.28 However, usnic acid 
extracted from Xanthoparmelia farinosa appeared to have some biological activity.29 While 




paucity of lichen antibiotic therapeutics may be related to lichen compound toxicities13 and 
this may argue for only topical use of lichen preparations. 
 
Anticancer activity 
 The anticancer activity of acetone extract from L. alphoplaca against MCF-7 cells 
showed promising results (Fig. 3), though the extracts of Acarospora socialis and 
Xanthoparmelia mexicana did not show significant anticancer activity (data not shown). The 
effective concentration where 50% of cells are killed (EC50) for Lobothallia alphoplaca was 
recorded at a lichen metabolite concentration of 87 µg mL-1,while the cisplatin positive 
control had an EC50 of 5 µg mL-1 (Fig. 3). This led to the conclusions that there is a 
statistically significant difference between the lichen treatment and the cisplatin control (P < 
0.05). Furthermore, the acetone solvent alone caused a 5% decrease in viability at the 
maximum concentration used (data not shown). Although the effective concentration of the 
acetone lichen extract was significantly higher than cisplatin, the similarities in the kinetics 
are evidence to suggest that the lichen extract may contain constituent(s) that acts via a 
similar mechanism of cisplatin.  Currently, we have undertaken experiments to isolate the 
active compound(s) from the lichen acetone extract which might provide us with a single 
compound of marked potency comparable to that of cisplatin. In addition, the observation 
of anti-proliferative activity of the L. alphoplaca extract (Fig. 3) encouraged us to undertake 
further investigations, currently in progress, on the toxicity of fractionated material of 




cell lines, as well as against primary cells. The latter approach is essential for the ultimate 
development of any lichen-derived compound to be used therapeutically. Toxin differential 
sensitivity between primary and neoplastic cells is paramount, yet the degree of selectivity is 
rarely investigated with lichen extracts.16, 17 Even if the L. alphoplaca active ingredients do 
not show a high degree of selectivity in future work, topical applications against epithelial 
cancers may prove useful, since general toxicity at the body surface may not be as critical. 
Preliminary evidence showed that MCF-7 cell cycle is arrested in the G2 phase, and that DNA 
synthesis may also be inhibited by the acetone extracts of L. alphoplaca (Table 2). 
Investigations are underway to identify specific active compounds in the L. alphoplaca 
extracts which inhibited neoplastic MCF-7 cells and determine the selectivity range against 
primary cells and a wider variety of cultured cancer cells that could lead to new and 






Figure 3-3: MCF-7 cell sensitivity to cisplatin (open circles) and L. alphoplaca acetone 





Figure 3-4: Concentration-effect curve representing MCF-7 cell sensitivity to cisplatin 
(dashed line) and L. alphoplaca acetone extract (solid line). 
 
Table 2: Flow Cytometry Data for MCF-7 cells treated with L. alphoplaca crude acetone 
extracts. 
Phase                              Acetone control Acetone extract 
G1                                     65.72 ± 1.07 52.51 ± 0.96 
S                                        14.01 ± 0.51 5.40 ± 0.34 
G2                                     22.33 ± 1.95 48.58 ± 2.33 
aG1, cells in Gap 1 phase of the cell cycle; S, cells in the Synthesis phase of the cell cycle; 






 In conclusion, significant biological activity was noted as follows: (1) ethanol (or 
methanol) extracts of A. socialis were effective in scavenging free radicals; (2) acetone or 
ethyl acetate extracts of X. mexicana inhibited growth of three species of Gram-positive 
bacteria; and (3) acetone extracts of L. alphoplaca were effective in inhibiting the growth of 
cancerous MCF-7 cells. Our work extends the list of lichen species with known biological 
activities, and we are encouraged by the fact that lichens are progressively found to be an 
effective source of biochemical entities useful in therapeutics and as food additives. 
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 The investigation into the three North American lichens encouraged the investigator 
to delve into the metabolite profile and bioactivity of other lichens, notably those of 
Northern Ontario. This led to the collection and analysis of a Northwestern Ontario lichen, 
Umbilicaria muhlenbergii, which has not yet been fully chemically characterized nor had a 
bioactivity evaluation completed. Initial investigation yielded promising results, leading to a 
broader investigation into its metabolites’ bioactivities and identities. The following 
manuscript, intended for publication within the Journal of the Science of Food and 









4 Extraction, separation, and identification of bioactive compounds 
from a Umbilicaria muhlenbergii, a Northern Ontario lichen 
4.1 Running Title: Bioactivity of Umbilicaria muhlenbergii 
4.2 Authors: Lyndon Letwin, Martina Agostino, Lada Malek, Zacharias Suntres, Lew P 
Christopher 
4.3 Abstract: 
BACKGROUND: The world of bioprospecting is constantly searching for novel sources 
of bioactive compounds. Lichens are emerging as a promising source of these 
compounds. In the present study, metabolites from a chemically uncharacterized 
Northern Ontario lichen were extracted, separated via silica gel column 
chromatography and Sephadex LH-20 column chromatography, tested for anticancer 
and antibiotic activity, and identified.  
RESULTS: This study found significant results in the areas of anti-cancer and antibiotic 
activities of Umbilicaria muhlenbergii. The crude extract was evaluated for bioactivity, 
then separated via silica gel 60 column chromatography. Two of these fractions were 
then separated further by Sephadex LH-20 column chromatography. The anticancer 
results are as follows: 1) Umbilicaria muhlenbergii acetone crude lichen extract 
exhibited an IC50 point of 13.3 μg mL-1, silica gel 60 separated fractions #1-6 of 8 
exhibited anticancer activity against MCF-7 cells, and Sephadex LH-20 separated 
fractions produced multiple bioactive fractions. Two of the silica gel 60 (SG 60) 




antibiotic activity of Umbilicaria muhlenbergii, the crude extract exhibited an MIC of 
22.5 μg/mL against Staphylococcus aureus, SG 60 fractions did not have statistically 
significant results, and Sephadex LH-20 separated fractions exhibited MIC points 
against Staphylococcus aureus. No statistically significant results were found with MICs 
against E. faecalis and P. aeruginosa.  
CONCLUSION: Umbilicaria muhlenbergii, has shown marked bioactivities after acetone 
extraction, silica gel 60, and Sephadex LH-20 separation of constituent compounds. 
The potential now exists to further investigate the identity of these compounds and 
further study their anticancer and antibiotic effects.  
4.4 Keywords: Umbilicaria muhlenbergii, anticancer, antibiotic, separation, extract 
4.5 Introduction 
 The research area of bioprospecting has always had the goal of sustainably and 
responsibly discovering useful and novel compounds from natural sources 1, 2. One area of 
research interest is that of lichens, organisms which produce a staggering array of 
potentially bioactive  compounds 3. There have been approximately 1050 lichen secondary 
metabolites identified, with over 350 of them exhibiting bioactivity 4, 5.  Interestingly, out of 
these 650 compounds produced by the fungal component of lichens, only approximately 60 
of them are also produced by free living fungi and higher plants 6. This indicates an ability of 
lichens to dedicate a greater amount of energy and resources towards secondary metabolite 




 The historical and ethnobotanical significance, physiology, and ecological 
characteristics of lichens have been previously investigated, but the search for bioactive 
compounds in lichens has not yet resulted in the identification of useful pharmaceuticals 7-9. 
The ever-pressing need for new solutions to the problem of antibiotic resistance, in addition 
to the persistent search for effective anticancer compounds, has led to the investigation of 
these abundant lichen secondary metabolites for pharmaceutically relevant compounds. 
  The lichen species Umbilicaria muhlenbergii (Ach.) Tuck (formerly Actinogyra 
muhlenbergii), also known as lesser rocktripe or plated rocktripe, is a species of foliose 
lichen native to much of the Great Lakes region and the East Coast of North America (Figure 
4-1). Preliminary work has shown promising results, warranting further inquiry. Previous 
work researching the bioactivity of several species within the genus Umbilicaria has been 
completed, with a handful of compounds being identified as responsible for bioactivity 10-12. 
These include umbilicaric acid, gyrophoric acid, and lecanoric acid 13. Though these lichenic 
acids tend to be ubiquitously present in Umbilicaria species, their exact concentrations and 
functional groups vary 13. The species of focus in this investigation, Umbilicaria 
muhlenbergii, has been analyzed as a bio-indicator species quite adept at uptake of heavy 
metals, but has not been the target of investigation for bioactivity nor specific identification 
of its secondary metabolites 14-18. This gap in the literature the species and geographical 





Figure 4-1: Umbilicaria muhlenbergii lichen. 
 
 The objective of this study was to probe into the in vitro bioactivity of Umbilicaria 
muhlenbergii extracts, with the intent of separating and possibly identifying the 
compound(s) responsible for Umbilicaria muhlenbergii’s anticancer and antibiotic 
properties. It is the authors’ expectation that the results garnered by this investigation could 
lead to further inquiry into the specific compound’s mechanisms of action and further 
development into useful therapeutic compounds.  
4.6 Experimental 
4.6.1 Lichen Investigated 
 In this study, the North American lichen Umbilicaria muhlenbergii (Ach) Tuck was the 
target organism (Figure 4-1). It was obtained from Onion Lake Dam Road, within the 




identified by Dr. Lada Malek of Lakehead University, and a voucher specimen was deposited 
into the Claude Garton Herbarium at Lakehead University. The collected lichen was stored in 
sealed 1 L jars at room temperature, in a cabinet without exposure to light, until the time of 
extraction.  
4.6.2 Chemicals and Instruments 
 Acetone, bacterial media, McFarland turbidity standards, mammalian cell culture 
media, fetal bovine serum (FBS), antibiotic-antimycotic (anti-anti), dimethyl sulfoxide 
(DMSO), silica gel 60 (SG60) and resazurin CellTiter-Blue® were purchased from Thermo 
Fischer Scientific Canada (Whitby, ON, Canada). Sephadex LH-20, 3-(4,5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide (MTT), propidium iodide, hexane, ethyl acetate, 
methanol, and acetonitrile were obtained from Sigma-Aldrich Canada (Oakville, ON, 
Canada). The instruments utilized in this investigation included a Biotek PowerWave XS 
microplate spectrophotometer (Biotek Instruments, Winooski VT, USA), a BD FACScalibur 
flow cytometer (BD Biosciences, San Jose, CA, USA), a BioLogic LP chromatography system 
(Bio-Rad Laboratories INC, Hercules, CA, USA), a BioFrac Fraction Collector (Bio-Rad 
Laboratories INC, Hercules, CA, USA) and a BMG FLUOstar Optima Microplate Reader (BMG 
Labtech, Offenburg, Germany). 
4.6.3 Lichen metabolite extraction 
 The lichen was pulverized in mortar and pestle, the lichen powder was shaken with 
10 g of lichen powder in 100 mL of solvent (acetone) at 120 rpm and 37oC for 24 h in an 
Innova© R42 incubator shaker (New Brunswick, Connecticut, USA), and thereafter filtered 




mass of the filtered solids from the original mass of ground lichen. After yield calculation, 
the extract was concentrated until it reached a set concentration of 10 mg mL-1.  
4.6.4 Silica gel 60 separation 
4.6.4.1 Column chromatography separation 
 A 600 mL, large-diameter glass column was chosen for the crude separation. First, 
250 mL of silica gel 60 (SG60), (Thermo Fischer Scientific Canda) was measured and poured 
into a 1 L beaker. Next, 1.5x volume of acetone (375 mL) was added to the 250 mL of SG60. 
This was thoroughly mixed via gentle stirring with a glass rod. Next, 100 mL of acetone was 
added to the column with the petcock closed. The mixed SG60 slurry was then carefully 
poured down a glass rod into the column. A further 200 mL of acetone was then added to 
the column, the petcock was opened, allowing the acetone to flow through the column to 
pack it. Once the acetone level reached 1 cm from the top of the column, the petcock was 
closed. The crude extract, at a concentration of 10 mg mL-1, was mixed with 50 mL of SG60 
in a mortar, and mixed with a pestle until well mixed and uniform in colour. Next, the 
Umbilicaria muhlenbergii crude extract slurry was added to the column, again by gently 
pouring along a glass rod into the column. Once the column was loaded, solvents of 
increasing polarity were poured through the column and allowed to elute via force of 
gravity. The solvents, in order of elution, are found in Table 3: Fraction number and solvents 







Table 3: Fraction number and solvents used for SG60 column elution. 
Fraction Number Solvent 
1 100% Hexane 
2 50% hexane, 50% ethyl 
acetate 
3 100% ethyl acetate 
4 100% acetone  
5 50% ethyl acetate, 50% 
methanol 
6 100% methanol 
7 90% methanol, 10% dH2O 
8 100% dH2O 
 
First, 200 mL of hexane was measured and gently poured into the column. The 
petcock was opened, allowing the eluent to flow through the column via force of gravity. A 
labelled screw-top flask was placed under the petcock to collect the eluent. Once the 
solvent level reached 1 cm above the silica gel, a new screw-top flask was placed under the 
petcock and 200 mL of 50% hexane, 50% ethyl acetate was added to the column. The same 
procedure was repeated for all eight of the solvent mixtures used.  
4.6.4.2 Concentration of silica gel 60 fractions 
 After collection, all eight collected silica gel 60 fractions were concentrated via rotary 
evaporator. First, eight scintillation vials were labelled, weighed, and had their weights 
recorded. Next, the volume of fraction 1 was loaded into a round bottom flask and attached 
to the rotary evaporator (BUCHI Corp, New Castle, DE, USA). The vacuum was turned, the 
flask was set to spin at a medium speed, and the flask was lowered into a water bath set at 




concentrated fraction was removed from the flask and pipetted into a scintillation vial via 
Pasteur pipette. The scintillation vial was opened and placed in a fume hood to allow the 
fraction to fully dry. The round bottom flask was then cleaned with the appropriate solvents, 
and the process was repeated with the next fraction.  
4.6.4.3 Resuspension of SG60 fractions at set concentration  
After all fractions had been dried fully, each scintillation vial was weighed and the 
mass of metabolites present calculated. Each vial was then resuspended to give a 
concentration of 10 mg mL-1. For fractions 1 and 2, DMSO was used for resuspension. For 
samples 3 and 4, acetonitrile was used. For fractions 5, 6, 7, and 8, methanol was used for 
resuspension.  
4.6.5 Sephadex LH-20 separation of fractions 
 SG60 fractions 5 and 6 both displayed prominent bioactivity against MCF-7 cells, 
along with a TLC result showing fewer compounds present (see Results), making the two 
fractions suitable candidates for further separation/purification. This further separation was 
accomplished with the use of Sephadex LH-20 column chromatography.  
 The column was prepared according to parameters set by the manufacturer, GE 
Healthcare 19. The 34 cm long, 1.5 cm diameter chromatography column filled with 60 mL of 
Sephadex LH-20 swelled in MeOH was connected to a BioLogic LP solvent pump (Bio-Rad) 
running at a solvent flow rate of 2 mL minute-1. The column outflow was managed by a 
BioFrac fraction collector (Bio-Rad) set to collect 2 mL fractions. Each fraction tube had been 




of 0.22 µm filtered SG60 fraction 5 was loaded into the column via syringe. The fraction was 
run until the column was clear. The column was flushed with 10% ethanol and 100% MeOH, 
then all steps were repeated for SG60 fraction 6.  
 After collection, all fractions were dried and weighed to determine the mass of 
metabolites present in each fraction. Fractions were then resuspended at a set 
concentration of 10 mg mL-1, if possible. All others had 100 μL of solvent added. Fractions 
were then transferred to 2.0 mL microcentrifuge tubes for sealed storage at 4 C in darkness 
until needed for bioactivity evaluation.  
4.6.6 Anticancer activity 
4.6.6.1 Maintenance of cell line  
 Human breast cancer MCF-7 cells (ATCC HTB-22) were purchased from the American 
Type Cell Culture Collection (ATCC, Manassas, VA, USA) and maintained in supplemented 
Dulbecco's Modified Eagle Medium (DMEM). The DMEM was supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin. The cell line was incubated at 37oC with a 
humidified 5% CO2 atmosphere.  
4.6.6.2 Anticancer activity assay 
 MCF-7 cells were seeded in a 96-well tissue culture microplate at a density of 10,000 
cells per well, then incubated at 37oC under 5% CO2 for 24 h. Next, the lichen extract or 
separated fraction was concentrated to a final metabolite concentration of 10.00 mg mL-1 to 
reduce the amount of acetone used in the treatment while simultaneously standardizing the 




wells and 150 µL of DMEM was added to each well. Next, 150 µL of lichen extract diluted in 
non-supplemented DMEM was added, in triplicate, to the first column of wells. Next, a serial 
dilution was performed (with non-supplemented DMEM) to dilute the metabolites. The 
concentration of lichen metabolites in the treatments ranged from 1000 µg mL-1 to 3.91 µg 
mL-1. Note that the lichen metabolite concentration must be expressed as a value of µg mL-1, 
as the active compounds have not yet been isolated and identified, thus negating the 
convention of molarity.  
 For clarity, the concentration of the positive control, cis-diammineplatinum(II) 
dichloride (cisplatin) is given in both molar concentration and mass per volume 
concentration. The positive control, cis-diammineplatium(II) dichloride (cisplatin), was 
prepared as a 198 ug mL-1 (0.66 mM) stock solution in sterile 0.9% NaCl solution. It was 
serially diluted from 0.6 µg mL-1 (2 µM) to 24 µg mL-1 (80 µM) for treatment conditions. The 
negative control was an untreated control group of MCF-7 cells which were grown in non-
supplemented DMEM. A 12 mM solution of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) in phosphate buffered saline was prepared, filter sterilized, 
and stored in the dark at 4oC. The plate was incubated at 37oC and 5% CO2 atmosphere for 
44 h, followed by the addition of 20 µL of MTT solution to each well. Next, the plates were 
incubated at 37oC and 5% CO2 for 4 h. The MTT solution was then removed from each well 
and replaced with 50 µL of dimethyl sulfoxide (DMSO). The plates were covered in foil and 
mixed on a Belly Dancer for 10 min. The absorbance was then measured at 490 nm and 650 




absorbance of the samples, controls, and negatives were measured and compared to 
baseline and negative control. All experiments were run in triplicate.  
4.6.6.3 Propidium Iodide flow cytometry 
 Cells were grown to confluency in a Corning T-75 cell culture flask, then 300,000 cells 
were seeded into a Corning Biolite 6-well multidisc tissue culture plate and allowed to grow 
for 24 hours. After 24 hours, cells were treated with increasing concentrations of methanol, 
acetone, Umbilicaria muhlenbergii crude extract, SG60 fractions 5 and 6, and Sephadex LH-
20 separated fractions. Overall, 48 samples were analyzed. The cells were treated for 48 
hours, afterwhich the following ethanol fixation and propidium iodide staining protocol was 
followed.  
4.6.6.4 Ethanol Fixation 
 After 48 hours of treatment time had passed, the media was removed from each 
well of the 6 well treatment plates and pipetted into labelled 15 mL centrifuge tubes. Next, 
500 μL of 0.1 % trypsin-0.02% EDTA solution (Sigma) was added to each well of the plates, 
which were then incubated for 5 minutes at 37 C. After incubation, 1.5 mL of SDMEM 
(Fischer Scientific) was added to each well to quench the trypsin-EDTA. The mixture of 
SDMEM, cells, and trypsin was then pipetted from each well into the appropriate 15 mL 
centrifuge tube which contained each specific wells’ earlier removed media. The 15 mL 
centrifuge tubes were then centrifuged at 500 RPM for 5 minutes at 4 C. After 
centrifugation, the supernatant was aspirated from each tube and the pellet resuspended in 
5 mL of PBS. This mixture was lightly vortexed, then again centrifuged with aforementioned 




centrifuge spin. After this final PBS wash, the supernatant was removed and 5 mL of cold, -
20 C ethanol was added drop-wise to each tube while the tube was being lightly vortexed. 
The tubes were then placed on ice for 10 minutes, then centrifuged at 500 RPM for 5 
minutes at 4 C. The ethanol was then removed from each tube, and 1 mL of propidium 
iodide solution (Sigma) was added to each tube. The tube was then lightly mixed, then 
incubated in a dark cabinet for 30 minutes at room temperature. Upon flow cytometry 
evaluation, each tube was lightly vortexed to suspend cells, then the suspension was 
pipetted into a flow cytometry tube (Fischer Scientific) and analyzed.  
4.6.6.5 Propidium Iodide Flow Cytometry Analysis 
 A BD FACScalibur system was utilized for flow cytometry analysis of the Umbilicaria 
muhlenbergii crude extract, silica gel 60 separated extract fractions, and Sephadex LH-20 
separated silica gel 60 fractions. The machine was first calibrated with non-treated MCF-7 
P12 cells. After calibration, each sample was run until 10,000 events were collected.  
4.6.7 Antibacterial activity 
4.6.7.1 Microorganisms and media 
 Bacteria used as test organisms in this study included both Gram-positive 
(Streptococcus pyogenes, Staphylococcus aureus, Enterococcus faecalis) and Gram-negative 
bacteria (Pseudomonas aeruginosa). All bacteria were acquired from ATCC and stored at -





 When taken out of cryostorage, one loop of bacteria was streak plated on Mueller 
Hinton II (MHII) agar and incubated at 37oC until individual colonies were sighted. Next, one 
colony was taken from the plate and used to inoculate 10 mL of MHII broth. The broth 
culture was incubated at 37oC until it reached a turbidity level which was equal to that of a 
0.5 McFarland Turbidity standard (approximately 1.5 x 108 CFU mL-1).  
4.6.7.2 Minimum Inhibitory Concentration (MIC) 
The MIC was determined in triplicate as follows: an 18-h broth culture (37oC and 150 
rpm) was diluted to 10 x 106 CFU mL-1 and 100 µL added to microplate, together with lichen 
extract dilutions (from .86 µg/mL  to 860 µg mL-1) and appropriate solvent and negative 
controls. Baseline absorbances at 600 nm were measured using BioTek PowerwaveXS 
spectrophotometer, followed by measuring the same plates incubated at 37oC for 24 h. At 
24 h, 40 µL of CellTiter-Blue® was added to each well of the microplate. The plates were 
incubated for 4 h at 37oC, then fluorescence was measured at 544 nm excitation/590 nm 
emission. To ensure accuracy of the spectrophotometer absorbance and fluorescence 
readings, 10 µL of each treatment condition was streaked onto LB agar plates, then 
incubated at 37oC for 24 h. After 24 h, the growth on each plate was noted.   
 
4.6.8 Statistical analyses 
 Statistical analyses were performed with the EXCEL, GraphPad Prism 6, and BD 
CellQuest Pro packages. All values were expressed as mean ± standard deviation (SD) of 
three parallel measurements. To determine statistical significance of cell death, a two-




4.7 Results and Discussion 
4.7.1 Chemical Separation 
4.7.1.1 Crude extract 
The multiple maceration extractions performed in this investigation proved to be 
both consistent and effective. Previous investigations, preliminary results, cost, and ease of 
handling considerations made acetone the solvent of choice for the extractions 20. The 
extraction consistently yielded an extract with a concentration of 3.40 ± 0.16 mg mL-1. The 
crude extract was then analyzed with thin layer chromatography, as shown in Figure 4-2.  
  
Figure 4-2: Thin layer chromatography of Umbilicaria muhlenbergii crude extract.   
Silica gel 60 plate, with 40 μL of crude extract loaded per spot. Solvent system used was 





The thin layer chromatography was analyzed and input into Wintabolites, a lichen 
metabolite database, but the large bands proved too mixed and ambiguous to return a 
specific compound or family 21. After crude extract bioactivity analysis was complete, the 
crude extract was separated via column chromatography. These separated fractions could 
then be visualized by TLC and prepared for further separation and chemical identification. 
4.7.1.2 Silica gel 60 separation 
 The silica gel 60 separation yielded eight fractions, all of which were resuspended in 
solvents according to the elution solvent used and the mass of metabolites present.  
 
Figure 4-3: Resulting 8 fractions from the silica gel 60 separation of Umbilicaria 
muhlenbergii crude extract. 
 These eight fractions were analyzed with thin layer chromatography, and again the 





Figure 4-4: Thin layer chromatography of Umbilicaria muhlenbergii silica gel 60 separated 
fractions 1-8. 20 x 20 cm glass backed silica gel 60 plate (Merck), solvent used was 170:30 
toluene:acetic acid. Image taken with 365 nm UV light illumination.  
 Anticancer activity testing showed that fractions 1-7 all exhibited some level of 
bioactivity (see Anticancer Activity). Analysis of the TLC plate in Figure 4-4 showed that SG60 
fractions 5 and 6 had the fewest number of compounds apparently present, while also 
showing promising anticancer activity. Due to the inherent complexity that comes with 
separating and identifying natural compound mixtures, these two fractions, having the 
fewest compounds, were the most logical choice for further investigation and separation. 





Figure 4-5: TLC of Umbilicaria muhlenbergii SG60 separated fractions 5 and 6.  
 The bands apparent in Figure 4-5 were input into Wintabolites, resulting in the 
identification of the main chemical families present in the mixtures. Fractions 5 and 6 
contained depsides, depsidones, anthraquinones, and xanthones.  Though TLC analysis 
produced many indicated chemical identities, the mixtures were still too complex to discern 
any concrete single compounds. This led to the use of Sephadex LH-20 as a separation media 
which was used to fractionate the SG60 fractions. 
4.7.1.3 Sephadex LH-20 separation 
Due to the SG60 fractions being a muddled mixture of compounds, further 
separation was deemed necessary. Sephadex LH-20 (GE Healthcare) was chosen as the 




substances 22-26. The Sephadex LH-20 also has proven to be an effective means of separation 
for despides, depsidones, and Xanthones, all of which are compounds of interest that can be 
found in Umbilicaria species 27-30.  
After separation and resuspension, the separated Sephadex LH-20 fractions were 
visualized via TLC. The SG60 fraction #6 was separated into 22 fractions via the Sephadex, 
resulting in a collection of 9 fractions which had enough mass to be resuspended and 
analyzed further. Other fractions not shown in Figure 4-6 either did not have any 
metabolites present, or did not contain sufficient metabolite mass to resuspend at a useful 
concentration and analyze.  
 
Figure 4-6: TLC of SG60 Fraction #6 Sephadex LH-20 Separated Fractions. Solvent used was 
170:30 toluene:acetic acid, plate used was silica gel 60 glass backed TLC plate, plate is 





This separation of SG60 fraction #6 on Sephadex LH-20 yielded fractions with 
significantly fewer compounds present, making them ideal for further analysis. Wintabolites 
analysis again confirmed the presence of depsides, depsidones, xanthones, and 
anthraquinones. The same results were found for the 46 fractions of SG60 fraction #5 being 
separated by Sephadex LH-20 (see Figure 4-7). Again, only fractions which had sufficient 
mass for resuspension and bioactivity analysis were included in the TLC experiments.  
The separation achieved by Sephadex LH-20 was enough to achieve some individual 
bands, while also ensuring that mixed bands did not have such a high number of compounds 
present. At this stage, the Sephadex LH-20 fractions shown in Figure 4-7 were utilitzed for 





anticancer and antibiotic activity evaluation. For future investigations into Umbilicaria 
muhlenbergii, these fractions could again be separated to attain the least complicated 
mixture possible. From there, positive identification of the compounds could be made via 
analytical chemistry methods.  
4.7.2 Antibacterial activity 
The antibacterial activity of the U muh crude acetone extract was evaluated using the 
minimum inhibitory concentration (MIC) broth microdilution method 31. This investigation 
revealed a MIC of 22.5 μg mL-1 against S. aureus bacteria. Tests against E. faecalis, S. 
pyogenes, and P. aeruginosa did not yield any statistically significant results.  
The SG60 separated fractions did not fare as well, with a lack of statistically relevant 
results against any of the bacteria tested (data not shown). Further separation of the SG60 
fractions with Sephadex LH-20 did yield statistically significant results though. Out of SG50 
fraction #5’s 46 Sephadex LH-20 separated fractions, five exhibited antibacterial activity 
against S. aureus (see Table 4).  
Table 4: MIC of Sephadex LH-20 Separated SG60 Fraction #5 against S. aureus. 







Though these five fractions showed activity against S. aureus, the full utility of the 




could be considered of useful pharmaceutical interest, as they are within the concentration 
range of existing antibiotics, though fractions 24, 25, and 38 are of concentrations which are 
much too high to be pharmaceutically relevant. As a result, most of these results are more 
valuable in an academic context than a medical one.  Again, a lack of statistically significant 
results of MIC against E. faecalis, S. pyogenes, and P. aeruginosa were found (data not 
shown).  
These findings are in line with previous lichen bioactivity investigations, where a lack 
of activity against gram-negative bacteria was noted 20.  This lack of activity against gram-
negative bacteria could indicate that the compounds are bioactive in a way that somehow 
affects the peptidoglycan cell wall of gram-positive bacteria. A compound or mixture of 
compounds with this specificity would not affect gram-negative bacteria.  
The presence and absence of antibacterial activity at different stages of fractionation 
and separation could also be indicative of a synergistic effect32, 33. The presence of a 
complex mixture of metabolites could be the key to the bioactivity of the extract, as the 
individual compounds present within the extract may not be effective as standalone 
treatments, but when combined, can have a potent effect 32, 34, 35. The number of 
compounds involved in this mixture could also greatly affect the potency, as evidenced by 
the crude extract and Sephadex LH-20 separated fractions exhibiting bioactivity, but the 
SG60 fractions being statistically insignificant.  
These antibacterial findings are promising in an era where the search for novel and 




as the Umbilicaria muhlenbergii lichen investigated here, are poised to become valuable 
troves of bioactive compounds, which are needed evermore as traditional antibiotics begin 
to confer resistance36, 37. The promising results yielded by this study indicate that 
Umbilicaria muhlenbergii, and other species within the genus, could be useful as a source of 
antibiotics. Previous investigations into other Umbilicaria species have exhibited antibiotic 
effects, such as Umbilicaria virginis inhibiting B. cereus, B. subtilis, S. aureus, K. pneumoniae, 
E. coli, P. aeruginosa, M. morganii, and Y. enterocolitica10. The activity against gram-negative 
bacteria is of note, as the differences in metabolites produced between Umbilicaria species 
could be used to determine which compounds are bioactive against which type of bacteria.  
Other Umbilicaria species have shown antifungal, antioxidant, anticancer, and 
antibacterial effects 10, 12, 38-40. The major bioactive secondary metabolites known to be 
found in the genus; gyrophoric acid, lecanoric acid, and umbilicaric acid, have also been 
evaluated for antibacterial activity 10, 11, 40. The activity of other species within the genus, 
coupled with the preliminary results of Umbilicaria muhlenbergii’s antibacterial abilities, 
warrant further investigation. Though outside of the scope of this study, a more systematic 
approach could be taken through analytical chemistry means, such as mass spectroscopy, to 
positively identify these antibacterial compounds. Once identified, the compounds could be 
synthesized, thereby opening the door to further research.   
One hurdle facing these lichen-originated compounds is that of lichen toxicity, which 
needs further investigation. Though promising, natural products from the genus Umbilicaria 
have not yet been moved out of the in vitro investigation stage, leaving open opportunity 




4.7.3 Anticancer Activity 
4.7.3.1 Crude extract anticancer activity 
The crude acetone extract of Umbilicaria muhlenbergii exhibited marked anticancer 
ability, having an effective concentration when 50% of the cells are killed (EC50 point) of 13.3 
μg mL-1 (Figure 4-8), while the cisplatin positive control had an EC50 of 5.8 μg mL-1 (Figure 
4-9). This shows a statistically significant difference between the lichen treatment and the 
cisplatin positive control (P<0.05). This compares favourably with previous lichen metabolite 
investigations undertaken, but with Umbilicaria muhlenbergii being effective at lower doses 
than other lichens investigated20. Furthermore, solvent death due to acetone caused a 5% 
decrease in cell viability at the highest concentration, and negligible cell death at lower 
concentrations (data not shown). 
 




























Figure 4-8: Survival of MCF-7 cells after 48-hour treatment with crude U. muhlenbergii 



























Figure 4-9: Survival of MCF-7 cells after 48-hour treatment with cisplatin chemotherapy 
drug. Cell survival analyzed via MTT assay. 
 
Though the Umbilicaria muhlenbergii crude extract needs a higher dose than the 
cisplatin for an equivalent level of cell death, the more aggressive dose response curve could 
suggest that the compounds found within the lichen extract may elicit an inhibitory effect 
similar to that of known chemotherapeutics such as cisplatin. 
The response of MCF-7 cells to the crude extract encouraged further investigation, 
which required the separation of the compounds to more concisely assess the bioactivity of 
the secondary metabolites found within the extract. This began with chemical separation of 
the crude extract via silica gel 60 (SG60) column chromatography. 
4.7.3.2 Silica gel 60 separated fractions anticancer activity 
All eight of the SG60 fractions were evaluated for anticancer activity against an MCF-7 
breast adenocarcinoma cell line, and all 8 fractions were found to be bioactive (Figure 4-10 
and Figure 4-11). All eight fractions had a significant effect on the cell viability, though their 




treatment with SG60 fractions 5 and 6 were noted, as their dose response curves differ from 
many of the others. This observation, in addition to the TLC data indicating fewer 
compounds present, encouraged further investigation into these fractions.  
Flow cytometry was utilized to gain insight into how these SG60 fractions and their 
metabolites were affecting the cells. Investigation of the cell cycle in cells treated with SG60 
fraction 5 yielded a result which was not statistically significant different from the untreated 
control group of cells (data not shown). The same was found when crude extract was tested; 
there was a negligible effect on the cell cycle (data not shown). Solvent control treated cells 
did not exhibit any significant effects (data not shown).  
The cell cycle differs significantly from the untreated control group for fraction 6 
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Figure 4-10: Dose response curve of MCF-7 cells exposed to increasing concentrations of 
solvents and silica gel 60 separated Umbilicaria muhlenbergii fractions 1-4. Cells were 
exposed to treatments for 48 hours, then viability was analyzed via MTT assay. 
Concentrations of treatment are log transformed. A is given in μL mL-1 for comparison to 
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Figure 4-11: Dose response curve of MCF-7 cells exposed to increasing concentrations of 
solvents and silica gel 60 separated Umbilicaria muhlenbergii fractions 5-8. Cells were 
exposed to treatments for 48 hours, then viability was analyzed via MTT assay. 








Figure 4-12: Propidium iodide stained MCF-7 cells, untreated growth control in TDMEM. 






Figure 4-13: Propidium iodide stained MCF-7 cells, treated with 253.3 μg mL-1 SG60 
Fraction 6. Go/G1 phase= 73.14% (M1 + M2), S phase= 17.27% (M3), G2/M=7% (M4) 
 Figure 4-13 shows a buildup of cells in the Go/G1 phase (73.14% of cells), which is 
indicative of cell cycle arrest. A pre-G1 accumulation is also suggestive of apoptotic cells, 





Figure 4-14: Propidium iodide stained MCF-7 cells, treated with 126.6 μg mL-1 SG60 
Fraction 6. Go/G1 phase= 66.3% (M1+M2), S phase= 27.18% (M3), G2/M=5.56% (M4) 
 
Figure 4-15: Propidium iodide stained MCF-7 cells, treated with 66.6 μg mL-1 SG60 Fraction 




The ability to elicit an arrest of the cell cycle was noted as the treatment 
concentrations were decreased (Figure 4-14 and Figure 4-15). The ability to affect the cell 
cycle at lower doses is paramount, as many natural products, including lichen metabolites, 
are toxic upon ingestion 41-44. Reducing the concentration to a level low enough that does 
not cause negative health effects would thereby make the compounds viable candidates as 
anticancer compounds.  
The induction of apoptosis via chemical means would be ideal, as apoptotic 
pathways are acted upon by currently utilized chemotherapeutic agents 45. Though a 
promising result, the simple analysis with propidium iodide falls short of the mark for 
definite apoptotic detection, as more sensitive methods are required to determine the 
mechanism at play.  
Other lichen compounds have been found to induce apoptosis in human cancer cell 
lines 46-49. These include compounds such as salazinic acid, stictic acid, protolichesterinic 
acid, usnic acid, and sporomoric acid 46-49. This inhibition of cellular proliferation and 
induction of apoptosis could make these lichen compounds a valuable source of anticancer 
compounds. This apoptotic evaluation of isolated and purified Umbilicaria muhlenbergii 
metabolites has yet to be completed, leaving room for further investigation. If purified 
compounds from Umbilicaria muhlenbergii do exhibit apoptotic effects as other lichen 
metabolites have, this would follow the suit of existing anticancer drugs, which are adept at 




4.7.3.3 Sephadex LH-20 separated fractions anticancer activity 
 Once the bioactivity of the silica gel fractions had been investigated, it was apparent 
that further separation was necessary to reduce the number of compounds being used to 
treat the cells. It was the investigator’s goal to achieve as few compounds as possible per 
fraction in order to identify individual or small groups of compounds.  
 SG60 fraction 5 was separated into 22 fractions with Sephadex LH-20, while SG60 
fraction #6 was separated into 46 fractions. Each of these fractions was evaluated for 
bioactivity against MCF-7 cells (Figure 4-16 and Figure 4-17).  






















































Figure 4-16: Survival of MCF-7 cells treated with 22 fractions from Sephadex LH-20 
separated silica gel 60 fraction #6. Silica gel 60 fraction #6 obtained from separation of 
Umbilicaria muhlenbergii crude extract. Treatment time was 48 hours. Each treatment 









































































































Figure 4-17: Survival of MCF-7 cells treated with 46 fractions from Sephadex LH-20 
separated silica gel 60 fraction #5. Silica gel 60 fraction #5 obtained from separation of 
Umbilicaria muhlenbergii crude extract. Treatment time was 48 hours. Each treatment 
well contained 50 μg of metabolites.  
 
 SG60 fraction 5’s Sephadex fractions showed potent bioactivity from fractions 10 
through 22, with the most bioactive fractions being 11, 12, 13, 14, 15, 19, 20, 21, and 22 
(Figure 4-16). For SG60 fraction 6, various areas of bioactivity were noted (Figure 4-17). Note 
that these bioactive fractions correspond with areas on the TLC plates where bands, 
consisting of similar compounds, are spread out laterally between several lanes on the plate. 
This indicates that a compound is shared between these bands, and that the compound in 
question is responsible for the MCF-7 cell death.  
 Propidium iodide flow cytometry analysis of the Sephadex LH-20 fraction treated 
cells did not produce any results of interest, with none of the fractions indicating cell cycle 
arrest (data not shown).  This could be due to the cells not possessing apoptotic effects, but 




could be possible that at the time of analysis, further necrosis of the cells and cellular 
breakdown could have occurred, leading to the results shown.  
 In conclusion, it was noted that Umbilicaria muhlenbergii: (1) acetone crude extract 
exhibits potent MCF-7 anticancer activity and antibacterial activity against select gram-
positive bacteria, (2) silica gel 60 separated fractions exhibit MCF-7 anticancer activity and 
the ability to arrest the cell cycle, and (3) Sephadex LH-20 separated fractions show MCF-7 
anticancer activity and antibacterial activity against select gram-positive bacteria. This work 
extends the evaluation of lichen metabolites to the species Umbilicaria muhlenbergii, and 
shows encouraging results which set up lichens as being an effective source of new chemical 
entities for eventual therapeutic use.   
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5 Thesis Conclusions and Future Directions 
 Overall, lichen secondary metabolites present an interesting source of bioactive 
compounds which could prove useful for pharmaceutical means. The extracts and 
subsequent fractions have proved to be potent inhibitors of cancerous cells, while 
simultaneously being an effective antibacterial compound against gram-positive bacteria 
and exhibiting antioxidant potential. Lobothallia alphoplaca exhibited anticancer activity, 
with an IC50 of 87 µg mL-1. Xanthoparmelia mexicana exhibited potent antibacterial 
properties, with a MIC of 20.9 µg mL-1 against S. aureus and 41.9 µg mL-1 against E. faecalis. 
Further investigation into the antibiotic effects of Xanthoparmelia mexicana need to be 
pursued, as further studies of their metabolites could yield valuable antibiotics. A more 
mechanistic or molecular approach to the antimicrobial experiments could now be pursued 
as well, allowing future researchers to determine exactly how the bacteria are responding to 
the metabolites.  
  Of particular interest to the author are the auspicious results of the Umbilicaria 
muhlenbergii evaluation. The in vitro bioactivities presented in this investigation pose a 
starting point for further research into Umbilicaria muhlenbergii. Antibacterial activity was 
noted with an MIC of 22.5 µg mL-1 against S. aureus, proving to be similar to that of 
Xanthoparmelia mexicana. It also showed a very strong anticancer tendency, with an IC50 of 
13.3 µg mL-1.  Even more interesting are the apparent abilities to arrest the cell cycle in MCF-
7 cells, as shown in Figure 4-15. Further investigation into the remaining SG60 fractions 
could also result in valuable results, as they all exhibited anticancer activity but were not 




mechanistic investigation into Umbilicaria muhlenbergii’s anticancer activities. While 
cisplatin, a common chemotherapeutic, was found to have an EC50 of 5.8 µg mL-1, 
Umbilicaria muhlenbergii crude extract was not too far off the mark of clinical relevance, 
especially being an unprocessed crude extract. Perhaps with further refinement and 
identification of particular bioactive compounds or combinations, a treatment of 
therapeutic value within a useful range of concentration could be discovered.  
  This proven anticancer and antibiotic ability can lead one to question whether other 
bioactivities will be present as well, such as antifungal or antioxidant. Some of the 
compounds could be pluripotent, making their discovery even more valuable.  
 Though promising, challenges must be overcome before further results can be 
gathered. One area of improvement would be the increase in sample collection. The lichen 
metabolites make up a very small fraction of the lichens mass, thereby causing diminishing 
returns as the metabolites are extracted and separated. With each separation, the 
metabolites are separated into smaller groups and lost through experimental processes, 
meaning that every subsequent step has a smaller and smaller concentration of metabolites 
to investigate. This leads to concentrations where the metabolites are un-testable, as they 
are in such low quantities that they cannot be resuspended in an appropriate solvent at a 
useful concentration. The difficulty faced in separating the compounds will have to be 
overcome as well. Many of the compounds are of very similar structure and/or molecular 
weight, so the separation becomes difficult. A lack of standards for these compounds also 
exacerbates the issue, as lichen metabolite standards are incredibly expensive. One 




20 column, thereby giving the ability to discern the unidentified compounds’ molecular 
weights. More advanced methods of separation will have to be employed as well.  
 Achieving better separation and higher concentrations of lichen metabolites would 
make identifying the compounds through HPLC, LC-MS, GC-MS, NMR, or a plethora of other 
analytical chemistry methods easier as well. Further work could increase the mass of lichens 
extracted, increasing throughput and increasing metabolite mass present.  
 Further inquiry through processes of flow cytometry could be pursued, as the 
mechanisms at play could be discerned using techniques such as caspase tagging, annexin-
PI, APO BrdU apoptosis assays, and more. Furthermore, other cell lines other than MCF-7 
could be treated with the metabolites to determine if they are effective against other cell 
types. Though in vivo anticancer work has not been a very prominent point in lichen 
bioactivity analysis, it could be pursued once compounds are positively identified, evaluated 
for in vitro toxicity, and either isolated or synthesized in sufficient quantities.  
 The results of the antibacterial assays indicate an antibiotic effect which is on the 
higher end, but still within, the range of useful concentrations for modern, in-use antibiotics.  
The separated fractions from Umbilicaria muhlenbergii could be applied towards a more 
broad-spectrum test of many different types of bacteria, thereby determining if the lichen’s 
metabolites have any specificity towards different bacteria. The small set of bacteria tested 
here was sufficient for a surface level evaluation of whether antibacterial activity was 
present, but it is non-exhaustive in terms of discerning the selectivity and overall 




which could lead to further studies of Umbilicaria’s antibiotic abilities. Few lichen 
metabolites have had their antibacterial mechanisms clarified, making investigation into 
mechanisms an attractive, novel, and productive area of future research.  
 In conclusion, lichens posses the ability to produce hundreds of different 
compounds, making them an attractive target for bioprospecting. After bioactivity analysis 
of Xanthoparmelia mexicana, Lobothallia alphoplaca, and Umbilicaria muhlenbergii, it is 
apparent that all three could contain valuable chemical entities that could be used for 
antibacterial and anticancer purposes. Further research into the topic will be required, but 
with these results, a precedence for further inquiry has been established.  
